Sun Pharma inks deal to commercialize Winlevi in Canada and the U.S.
Category: #business  By Pranali Mehta  Date: 2021-07-27
  • share
  • Twitter
  • Facebook
  • LinkedIn
Sun Pharma inks deal to commercialize Winlevi in Canada and the U.S.
  • Cassiopea S.p.A will be the exclusive supplier, as per the new agreement.
  • Sun Pharma’s share price grew by 1.06% to 9.43 USD following the announcement.

Sun Pharmaceutical Industries Limited announced to have signed an agreement with Cassiopea S.p.A to commercialize Winlevi (clascoterone cream 1%) in Canada and the United States. Sun Pharma’s share price grew by 1.06% to 9.43 USD following its recent announcement.

As per the agreement, Sun Pharma will own the exclusive rights to commercialize Winlevi in Canada and the United States while Cassiopea will be the exclusive supplier. Moreover, the Italy-based pharmaceutical company will receive an upfront payment of USD 45 million in addition to commercial milestones worth USD 190 million.

The United States Food and Drug Administration had approved Winlevi (clascoterone cream 1%) for topical treatment of acne vulgaris among patients who are 12 years of age and older. The last time the FDA approved an acne drug with an advanced mechanism was approximately 40 years ago.

Notably, acne is the most common skin condition in the U.S. and affects up to 50 million Americans each year. Winlevi should be available in the United States by October 2021.

CEO of North America Sun Pharma, Abhay Gandhi was quoted saying that the company is pleased to collaborate with Cassiopea. He further added that the addition of Winlevi in the company’s product portfolio will strengthen its presence in the acne treatment vertical. 

Meanwhile, Cassiopea CEO Diana Harbort mentioned that the new agreement will help the company to leverage Sun Pharma’s strong presence in U.S. dermatology. The transaction will also allow Cassiopea to generate substantial returns, which will further benefit the development of pipeline drugs.

Sun Pharmaceutical Industries Limited is India’s top pharmaceutical company and the world’s fourth-largest generic pharma company.

Source Credits—

https://www.business-standard.com/article/news-cm/sun-pharma-gains-on-deal-for-acne-cream-with-cassiopea-121072600552_1.html

  • share
  • Twitter
  • Facebook
  • LinkedIn

About Author

Pranali Mehta

Pranali Mehta    

Pranali Mehta boasts of over three years of experience as a content writer. Having completed her graduation in chemical engineering, she worked as safety & environment associate in a chemical company for a year. Harnessing her passion for writing however, Pranali deci...

Read More >>

More News By Pranali Mehta

Air New Zealand exploring low-carbon tech to reduce fleet emission
Air New Zealand exploring low-carbon tech to reduce fleet emission
By Pranali Mehta

Air New Zealand Ltd. recently stated that it is learning to utilize low-carbon technologies such as hybrid, electric, or hydrogen-powered aircraft to drastically cut emissions from shorter and regional flights by 2030. Aviation accounts for about 2....

Siemens Gamesa raises capacity of 5.X wind turbine platform to 6.6MW
Siemens Gamesa raises capacity of 5.X wind turbine platform to 6.6MW
By Pranali Mehta

Renewable energy major, Siemens Gamesa has successfully increased the capacity of its next-generation onshore wind turbine platform, the Siemens Gamesa 5.X. With this upgrade, output of the platform’s SG 6.6-155 and SG 6.6-170 turbines has bee...

Amazon launches its largest fulfillment center in Bengaluru, India
Amazon launches its largest fulfillment center in Bengaluru, India
By Pranali Mehta

E-commerce major Amazon India has unveiled the largest fulfillment center in Bengaluru, which reportedly comes with a capacity of over 2.4 million cubic feet. The company mentioned in its official statement this new infrastructural expansion will pr...